Globus Medical (GMED) announced that a Delaware jury has returned a verdict in favor of Globus in its patent infringement litigation against Life Spine. The jury found that Life Spine’s Prolift family of implants infringed several claims of a valid Globus patent and awarded Globus both lost profits and reasonable royalty damages. The technology at issue involves expandable spinal fusion implants, an important advancement in patient care that can help improve outcomes in spinal surgery. In addition to the Life Spine case, Globus has a separate patent infringement litigation pending against Alphatec involving expandable implant and retractor technology.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical’s Earnings Call Highlights Robust Growth and Strategic Advances
- Globus Medical price target lowered to $66 from $76 at Wells Fargo
- Globus Medical Reports Strong Q2 2025 Growth
- Globus Medical reports Q2 non-GAAP EPS 86c, consensus 75c
- Globus Medical sees FY25 non-GAAP EPS $3.00-$3.30, consensus $3.16